Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 3865Neoplasms 2991Prostatic Neoplasms 1754Colorectal Neoplasms 1431Lung Neoplasms 1332Motor Activity 805Head and Neck Neoplasms 686Pancreatic Neoplasms 664Colonic Neoplasms 655Uterine Cervical Neoplasms 653Carcinoma, Hepatocellular 632Carcinoma, Non-Small-Cell Lung 631Rectal Neoplasms 571Stomach Neoplasms 547Brain Neoplasms 486Ovarian Neoplasms 441Anxiety Disorders 420Pain 419Neoplasm Metastasis 385Esophageal Neoplasms 384Polycystic Ovary Syndrome 376Precursor Cell Lymphoblastic Leukemia-Lymphoma 354Urinary Bladder Neoplasms 351Fatigue 340Multiple Myeloma 323Melanoma 323Lymphoma 306Depression 306Endometrial Neoplasms 290Liver Neoplasms 280

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Dermatologic Complications × Clear all
NCT00498992 2013-09-20

Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer

National Cancer Institute (NCI)

Phase NA Unknown
20 enrolled
Other solid neoplasm

Dermatologic Complications

Data powered by HemOnc (CC BY 4.0) Colophon ⚡